Therapy Areas: Vaccines
AstraZeneca still waiting for US FDA decision to resume COVID-19 vaccine trials in US
24 September 2020 -

Chief Executive Pascal Soriot of British pharmaceutical company AstraZeneca Plc (STO:AZN)(LON:AZN) said that the company is still waiting for the go-ahead from the US drug regulator, the Federal Drug Administration (FDA), to restart the clinical trial of its potential COVID-19 vaccine in the US, Reuters news agency reported on Thursday.

Reportedly, the US trial of AstraZeneca's COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the US have resumed.

According to US Health and Human Services Secretary Alex Azar, this continued suspension showed the US FDA took vaccine safety seriously.

Oxford University has stated the illness in a British participant that triggered the trail pause on 6 September 2020 may not have been associated with the vaccine, Reuters added.



Related Headlines